Vanhoutte P M
Fed Proc. 1983 Feb;42(2):233-7.
The release of 5-hydroxytryptamine (5-HT) from aggregating platelets may trigger acute vasospastic episodes of larger arteries, which can lead to tissue ischemia, particularly in the coronary and cerebral circulations. In hypertensive humans and animals, 5-HT may play a role in the maintenance of the chronic increase in peripheral resistance. This is suggested by the observations that 1) in several models of chronic hypertension there is a specific increase in the responsiveness of the blood vessel wall to the vasoconstrictor properties of 5-HT and a delayed tachyphylaxis to the monoamine; 2) the ability of hypertensive animals to clear 5-HT from the blood is reduced, and the platelets of hypertensive patients take up less 5-HT than those of normotensive humans; their activation to release 5-HT is accelerated; and 3) ketanserin, a 5-HT2-serotonergic antagonist devoid of agonistic properties, lowers arterial blood pressure in hypertensive humans and animals.
聚集的血小板释放5-羟色胺（5-HT）可能引发较大动脉的急性血管痉挛发作，这可能导致组织缺血，尤其是在冠状动脉和脑循环中。在高血压患者和动物中，5-HT可能在维持外周阻力的慢性增加中起作用。以下观察结果提示了这一点：1）在几种慢性高血压模型中，血管壁对5-HT血管收缩特性的反应性有特异性增加，并且对单胺有延迟的快速耐受性；2）高血压动物从血液中清除5-HT的能力降低，高血压患者的血小板比血压正常者的血小板摄取的5-HT更少；它们释放5-HT的激活加速；3）酮色林是一种无激动特性的5-HT2-血清素能拮抗剂，可降低高血压患者和动物的动脉血压。
